Physician profile
Sumit Bose
NPI 1306163902
$4,922.66
in general payments reported to CMS, 2019-2025
21 companies · $2,192 in 2025
The $2,192 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $88.39 · 2021: $84.25 · 2022: $420 · 2023: $567 · 2024: $1,392 · 2025: $2,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,016 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,015.67 |
| Education | $135.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,205.51 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $720.98 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Amgen INC. | $575.68 | 2022-2025 | Tezspire |
| Glaxosmithkline, LLC. | $405.13 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $381.85 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $337.85 | 2023-2025 | |
| Csl Behring | $204.73 | 2024-2025 | Hizentra |
| Genentech USA, INC. | $188.16 | 2024-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $152.43 | 2024-2025 | Cuvitru, Hyqvia, Takhzyro |
| Galderma Laboratories, L.P. | $136.40 | 2025 | Nemluvio |
| Pfizer INC. | $102.05 | 2024-2025 | |
| Grifols USA, LLC | $86.70 | 2024-2025 | Xembify, Gamunex-C |
| Ars Pharmaceuticals Operations, INC. | $85.27 | 2025 | Neffy |
| Alk-Abello, INC | $65.24 | 2023-2024 | Grastek, Ragwitek, Odactra |
| Biocryst US Sales Co., LLC | $61.39 | 2021-2024 | Orladeyo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hospira, INC. | $58.95 | 2024-2025 | |
| Kaleo, INC. | $50.10 | 2020-2024 | Auvi-Q |
| Jubilant Hollisterstier LLC | $48.48 | 2025 | |
| Circassia INC. | $19.01 | 2019 | |
| Optinose US, INC. | $18.82 | 2024 | |
| Incyte Corporation | $17.93 | 2025 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Bose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.